Rubab et al. (40) developed curcumin- nanostructured lipid carriers CUR-NLCs carriers (CUR-NLCs) and replicated the depression and anxiety model with LPS to study their neuroprotective effects in this model, and from histological and immunohistochemical analyses, CUR-NLCs improved brain tissue structure, inhibited the expression of p-NF-κB, TNF-α, and COX-2 in brain tissue, and enhanced the neuroprotective effects of curcumin, which could be used as a treatment for depression and anxiety as a potential drug. The gene discussed is PTGS2; the disease is depressive symptom measurement.